Table of Contents
- Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Pharmacogenomics in Practice
- Leaders in the Implementation of PGx
- Celera Genomics
- Illumina
- Perlegen Sciences
- Well-Documented Patient Data Are Paramount
- DeCode Genetics-Icelandic Population
- Spectrum Expert Commentary: Difficulties in Using Founder Populations
- The Mayo Clinic-Olmsted County Epidemiology Data
- Genizon-Quebec French Canadian Founder Population
- Industry's Current Use of Pharmacogenomics
- Preclinical Drug Development
- DeCode Genetics-Identifying New Drug Targets
- Improving Safety and Efficacy of New Drugs
- Patient Segmentation
- Genentech/Roche/Chugai's Trastuzumab (Herceptin)
- Clinical Data/Genaissance's Vilazodone
- Perlegen's MCC-555
- Encode's Information-Rich Clinical Trials
- Drug Dosing and Metabolism
- NeoPharm's LE-SN38
- Warfarin (Bristol-Myers Squibb's Coumadin)
- Azathioprine and Mercaptopurines
- Adverse Drug Reactions
- GlaxoSmithKline's Abacavir (Ziagen)
- Eli Lilly's Atomoxetine (Strattera)
- Post-Marketing Efficacy Issues
- Epidermal Growth Factor Receptor-Based Drugs
- Clinical Data and Genaissance's STRENGTH and CARING Studies
- Major Challenges
- Regulatory Issues
- Reimbursement, Ethical, and Legal Issues
- Spectrum Expert Commentary: FDA Establishes New Processes:
- Pharmacogenomic Data Submissions and a Drug-Test Codevelopment Pathway
- Outlook
Tables
- 1. Financial Position of Key PGx Leaders, FY05
- 2. Select Celera Collaborations
- 3. Disease Correlations Identified by Celera
- 4. Select Perlegen Collaborations
- 5. Populations for Disease Correlation and PGx Studies
- 6. Effect of Genotype on Drug-Drug Interactions
- A. Examples of Different Categories of Biomarkers
- 7. Select PGx Diagnostics
Figures
- 1. Potential of PGx in Practice
- 2. Founder Populations
- 3. Genomewide Scans and SNP Mapping
- 4. Genome-Based Drug Doses for Antidepressants
- 5. UGT1A1 Genotype Testing Before Irinotecan Rx
- A. Drug-Test Codevelopment Process
|
Related Report
|